Drug Profile
Quemliclustat - Arcus Biosciences
Alternative Names: AB-680; Small molecule CD73 inhibitor - Arcus BiosciencesLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Arcus Biosciences
- Developer Arcus Biosciences; Gilead Sciences; UCLAs Jonsson Comprehensive Cancer Center
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Phosphonic acids; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cholangiocarcinoma; Non-small cell lung cancer; Pancreatic cancer
- Phase I/II Colorectal cancer
- No development reported Cancer
- Discontinued Prostate cancer
Most Recent Events
- 01 Feb 2024 Arcus Biosciences terminates a phase-I/II trial in Adenocarcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) and Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV) due to early accrual (NCT05688215)
- 16 Jan 2024 Updated adverse events and efficacy data from the phase-I ARC-8 trial in Pancreatic cancer presented by Arcus Biosciences at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 01 Dec 2023 Phase-II clinical trials in Cholangiocarcinoma (Late-stage disease, Recurrent, Metastatic disease) in USA (IV) (NCT06048133)